Safety of parecoxib when used for more than 3 days for the management of postoperative pain.
Pain Manag
; 7(5): 383-389, 2017 Sep.
Article
in En
| MEDLINE
| ID: mdl-28589749
ABSTRACT
AIM:
To assess parecoxib safety when used for >3 days for postoperative pain management.METHODS:
Treatment-emergent adverse event (TEAE) occurrence after day 3 was examined in a pooled analysis of three placebo-controlled trials of parecoxib following general or gynecologic surgery, or total hip arthroplasty. A total of 358 patients received parecoxib, and 318 placebo.RESULTS:
Mean treatment duration was similar between treatment groups. The overall frequency of all TEAEs after day 3 was also similar between treatment groups. Most TEAEs occurred in <1% of patients after day 3; frequencies were similar between treatment groups. Most TEAEs were considered mild or moderate in severity.CONCLUSION:
TEAE occurrence in patients receiving parecoxib for >3 days was low and similar to placebo after treatment day 3.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pain, Postoperative
/
Cyclooxygenase 2 Inhibitors
/
Isoxazoles
Type of study:
Clinical_trials
/
Etiology_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Pain Manag
Year:
2017
Document type:
Article
Affiliation country:
United States